Sugi Predict

Sugi Predict / Compounds / SCHEMBL3205660

SCHEMBL3205660

SCHEMBL3205660

CCOC(=O)CC(CC(=O)O)CC(=O)OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.46
▸ MGAM O43451 1/20 0.46
▸ SI P14410 1/20 0.46
▸ MGAM2 Q2M2H8 1/20 0.46
▸ ALDH1A1 P00352 7/20 0.40
▸ TSHR P16473 4/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ ALOX15 P16050 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CHRM1 P11229 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TRPA1 O75762 1/20 0.39
▸ CYP2D6 P10635 2/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.36
▸ HCAR2 Q8TDS4 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ GSK3A P49840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290966 0.88 TSHR (0.44) GAAMGAMSIMGAM2TSHR
SCHEMBL27729213 0.88 TSHR (0.44) GAAMGAMSIMGAM2TSHR
SCHEMBL27577255 0.81 MGAM (0.41) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL4298002 0.81 CACNA2D1 (0.50) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL3291696 0.79 CACNA2D1 (0.53) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL15969817 0.79 CACNA2D1 (0.53) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL3291702 0.79 CACNA2D1 (0.53) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL1456370 0.79 MGAM (0.52) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL21801003 0.78 TSHR (0.38) GAAMGAMSIMGAM2TSHR
SCHEMBL21801004 0.78 TSHR (0.38) GAAMGAMSIMGAM2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186633-A1 METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS SERAC HEALTHCARE LTD (GB) 2025-06-12 — — US disclosed
WO-2023166305-A1 METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS SERAC HEALTHCARE LTD (GB) 2023-09-07 — — WO disclosed
US-11723991-B2 Radiopharmaceutical compositions SERAC HEALTHCARE LIMITED (GB) 2023-08-15 — — US disclosed
US-20210060189-A1 RADIOPHARMACEUTICAL COMPOSITIONS SERAC HEALTHCARE LIMITED (GB) 2021-03-04 — — US disclosed
US-10758635-B2 Radiopharmaceutical compositions SERAC HEALTHCARE LIMITED (GB) 2020-09-01 — — US disclosed
EP-2598175-B1 RADIOPHARMACEUTICAL COMPOSITIONS SERAC HEALTHCARE LTD (GB) 2020-05-20 — — EP disclosed
EP-2680888-B1 TECHNETIUM LABELLED PEPTIDES GE HEALTHCARE LTD (GB) 2017-10-18 — — EP disclosed
US-9259496-B2 Technetium labelled peptides GE HEALTHCARE LIMITED (GB) 2016-02-16 — — US disclosed
US-8852550-B2 Chelator conjugates GE HEALTHCARE LIMITED (GB) 2014-10-07 — — US disclosed
EP-1991526-B1 Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (PBR) HAMMERSMITH IMANET LTD (GB) 2014-02-12 — — EP disclosed
EP-1404377-B1 IMPROVED CHELATOR CONJUGATES GE HEALTHCARE LTD (GB) 2005-09-21 — — EP disclosed
EP-1567141-A1 LABELED MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR IMAGING CARDIOVACULAR DISEASES GE Healthcare Limited (GB) 2005-08-31 — — EP disclosed
EP-1549317-A1 IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES GE Healthcare Limited (GB) 2005-07-06 — — EP disclosed
WO-2005053752-A2 NOVEL IMAGING AGENTS COMPRISING CASPASE-3 INHIBITORS GE HEALTHCARE LIMITED (GB) 2005-06-16 — — WO disclosed
US-20040258619-A1 Diaminedioxime radiometal complexes GE HEALTHCARE LIMITED (GB) 2004-12-23 — — US disclosed
WO-2004069365-A1 DIAGNOSTIC IMAGING AGENTS WITH MMP INHIBITORY ACTIVITY GE HEALTHCARE LIMITED (GB) 2004-08-19 — — WO disclosed
WO-2004052357-A1 LABELED MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR IMAGING CARDIOVASCULAR DISEASES GE HEALTHCARE LIMITED (GB) 2004-06-24 — — WO disclosed
WO-2004032936-A1 IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES AMERSHAM PLC (GB) 2004-04-22 — — WO disclosed
EP-1404377-A2 IMPROVED CHELATOR CONJUGATES GE Healthcare Limited (GB) 2004-04-07 — — EP disclosed
WO-2003006070-A2 IMPROVED CHELATOR CONJUGATES AMERSHAM PLC (GB) 2003-01-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040258619-A1 Diaminedioxime radiometal complexes DDO, DDT, DAO GAA 1115/4885MGAM 618/4885SI 1951/4885
US-11723991-B2 Radiopharmaceutical compositions TYMP, KIT, CHEK1 GAA 1458/4885MGAM 3399/4885SI 180/4885
US-20250186633-A1 METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS ITGB3, ITGB5, ITGAV GAA 2184/4885MGAM 3238/4885SI 1095/4885
US-20210060189-A1 RADIOPHARMACEUTICAL COMPOSITIONS TYMP, KIT, CHEK1 GAA 1458/4885MGAM 3399/4885SI 180/4885
US-10758635-B2 Radiopharmaceutical compositions TYMP, KIT, CHEK1 GAA 1390/4885MGAM 3520/4885SI 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.